{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:19:10Z","timestamp":1790983150029,"version":"4.1.0"},"reference-count":12,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Oncol"],"abstract":"<jats:p>Introduction: Enfortumab vedotin plus pembrolizumab (EV-P) is a new first-line treatment for metastatic urothelial carcinoma; however, its safety and efficacy in patients undergoing maintenance hemodialysis remain unclear because such patients were excluded from pivotal clinical trials. We report 2 hemodialysis patients with metastatic urothelial carcinoma treated with EV-P. Case Presentation: The first patient was a 78-year-old man with bladder cancer who developed pulmonary metastases. Because he also had a history of primary lung adenocarcinoma, computed tomography-guided biopsy was performed and confirmed metastatic urothelial carcinoma. EV-P was initiated on non-dialysis days. Grade 1 skin toxicity developed and required topical corticosteroid treatment and stepwise dose reduction of enfortumab vedotin. After three cycles, computed tomography showed a partial response, which was maintained after seven cycles and remained durable for 11 months after treatment initiation, even after treatment discontinuation. The second patient was a 62-year-old man with right upper tract urothelial carcinoma who developed multiple liver metastases and peritoneal dissemination after robot-assisted right nephroureterectomy. EV-P was initiated on non-dialysis days. After three cycles, computed tomography showed shrinkage of the liver metastases and peritoneal lesions, consistent with a partial response. At the latest follow-up, he had completed nine cycles, and the response was maintained without severe adverse events. Conclusion: These cases suggest that EV-P may be a treatment option for selected hemodialysis patients with metastatic urothelial carcinoma.<\/jats:p>","DOI":"10.1159\/000553314","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:57:40Z","timestamp":1782845860000},"page":"1138-1147","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Efficacy of Enfortumab Vedotin and Pembrolizumab in 2 Hemodialysis Patients with Metastatic Urothelial Carcinoma: A Case Series"],"prefix":"10.1159","volume":"19","author":[{"given":"Akihiro","family":"Maeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Tobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kakinoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000521979"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000530780"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.12736"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.77948"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0242-5"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01369-0"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1326715"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.21873\/cdp.10481"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-04045-2"}],"container-title":["Case Reports in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000553314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:00:51Z","timestamp":1786118451000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000553314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000553314","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.32819906","asserted-by":"subject"}]},"ISSN":["1662-6575"],"issn-type":[{"value":"1662-6575","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}